TARGETING ATRIAL MYOPATHY: DOSE DEPENDENT MANNER OF SGLT2 INHIBITOR IN PREVENTING ELECTRICAL AND STRUCTURAL REMODELLING IN METABOLIC SYNDROME RAT MODEL

Clicks: 15
ID: 331370
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #260 of 330 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 330 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background and Aims Atrial myopathy, a substrate for atrial fibrillation (AF) driven by structural and electrophysiological remodeling, is closely linked to metabolic syndrome (MetS). Empagliflozin (EMPA), an SGLT2 inhibitor with established cardioprotective properties, has not been fully evaluated in the context of atrial myopathy. This study examined its dose-dependent atrial effects in a Wistar rat MetS model. Methods Twenty-four male Wistar rats were allocated into four groups (n=6): healthy controls, MetS (high-fat high-sugar diet with streptozotocin over 16 weeks), MetS + EMPA 10 mg/kg/day, and MetS + EMPA 30 mg/kg/day. Under standardized anesthesia, surface ECG, echocardiography, and transesophageal electrophysiology studies were performed to assess P wave duration, left atrial (LA) length and area, isovolumetric relaxation time (IVRT), atrial effective refractory period (AERP), and corrected sinus node recovery time (CSNRT). Results MetS significantly prolonged P wave duration (p=0.0057), enlarged LA length (p=0.0022) and area (p=0.0073), elevated IVRT (35.60 vs. 19.19 ms; p<0.0001), and shortened AERP (p=0.0106) compared to controls. Both EMPA doses attenuated P wave prolongation and LA dilation. AERP was significantly preserved in the EMPA 10 mg/kg/day group versus MetS (p=0.0356). CSNRT differed significantly across groups (p=0.0468), without reaching pairwise significance after adjustment. Conclusion MetS induces multidimensional atrial myopathy encompassing structural dilation, diastolic dysfunction, conduction delay, and abbreviated refractoriness. Empagliflozin attenuated these alterations in a partially dose-dependent manner, supporting its candidacy as a preventive strategy against MetS-related AF.Figure 1.(A) Electrophysiological Tracings, (B) Echocardiography
Reference Key
openalex_W7220451929 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors M Afifuddin, A Rizal, M S Rohman, Fatchiyah, H Sujuti, A F Rahimah, W Karolina, C T Tjahjono, V A G Hose
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag119.003
URL
https://doi.org/10.1093/eurheartjsupp/suag119.003
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.